China
· Delayed Price · Currency is CNY BGI Genomics Statistics
Total Valuation
BGI Genomics has a market cap or net worth of CNY 13.54 billion. The enterprise value is 9.19 billion.
| Market Cap | 13.54B |
| Enterprise Value | 9.19B |
Important Dates
The next estimated earnings date is Friday, October 25, 2024.
| Earnings Date | Oct 25, 2024 |
| Ex-Dividend Date | Jul 4, 2024 |
Share Statistics
BGI Genomics has 381.35 million shares outstanding. The number of shares has increased by 1.54% in one year.
| Shares Outstanding | 381.35M |
| Shares Change (YoY) | +1.54% |
| Shares Change (QoQ) | +5.02% |
| Owned by Insiders (%) | 1.76% |
| Owned by Institutions (%) | 10.22% |
| Float | 183.46M |
Valuation Ratios
The trailing PE ratio is 241.67.
| PE Ratio | 241.67 |
| Forward PE | n/a |
| PS Ratio | 3.55 |
| PB Ratio | 1.53 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.49, with an EV/FCF ratio of -15.74.
| EV / Earnings | 149.89 |
| EV / Sales | 2.21 |
| EV / EBITDA | 18.49 |
| EV / EBIT | 130.69 |
| EV / FCF | -15.74 |
Financial Position
The company has a current ratio of 2.74, with a Debt / Equity ratio of 4.38.
| Current Ratio | 2.74 |
| Quick Ratio | 2.41 |
| Debt / Equity | 4.38 |
| Debt / EBITDA | 0.90 |
| Debt / FCF | -0.76 |
| Interest Coverage | 0.82 |
Financial Efficiency
Return on equity (ROE) is 0.63% and return on invested capital (ROIC) is 0.42%.
| Return on Equity (ROE) | 0.63% |
| Return on Assets (ROA) | 0.33% |
| Return on Capital (ROIC) | 0.42% |
| Revenue Per Employee | 1.11M |
| Profits Per Employee | 16,341 |
| Employee Count | 3,752 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 3.41 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.83% in the last 52 weeks. The beta is 0.64, so BGI Genomics's price volatility has been lower than the market average.
| Beta (5Y) | 0.64 |
| 52-Week Price Change | -34.83% |
| 50-Day Moving Average | 35.43 |
| 200-Day Moving Average | 41.18 |
| Relative Strength Index (RSI) | 43.55 |
| Average Volume (20 Days) | 2,115,295 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BGI Genomics had revenue of CNY 4.15 billion and earned 61.31 million in profits. Earnings per share was 0.15.
| Revenue | 4.15B |
| Gross Profit | 2.10B |
| Operating Income | 70.32M |
| Pretax Income | 78.20M |
| Net Income | 61.31M |
| EBITDA | 436.65M |
| EBIT | 70.32M |
| Earnings Per Share (EPS) | 0.15 |
Balance Sheet
The company has 4.94 billion in cash and 445.78 million in debt, giving a net cash position of 4.50 billion or 11.79 per share.
| Cash & Cash Equivalents | 4.94B |
| Total Debt | 445.78M |
| Net Cash | 4.50B |
| Net Cash Per Share | 11.79 |
| Equity (Book Value) | 10.19B |
| Book Value Per Share | 23.28 |
| Working Capital | 4.87B |
Cash Flow
In the last 12 months, operating cash flow was 325.97 million and capital expenditures -909.94 million, giving a free cash flow of -583.97 million.
| Operating Cash Flow | 325.97M |
| Capital Expenditures | -909.94M |
| Free Cash Flow | -583.97M |
| FCF Per Share | -1.53 |
Margins
Gross margin is 50.53%, with operating and profit margins of 1.69% and 1.48%.
| Gross Margin | 50.53% |
| Operating Margin | 1.69% |
| Pretax Margin | 1.88% |
| Profit Margin | 1.48% |
| EBITDA Margin | 10.52% |
| EBIT Margin | 1.69% |
| FCF Margin | -14.07% |
Dividends & Yields
This stock pays an annual dividend of 0.10, which amounts to a dividend yield of 0.29%.
| Dividend Per Share | 0.10 |
| Dividend Yield | 0.29% |
| Dividend Growth (YoY) | -90.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 10.08% |
| Buyback Yield | -1.54% |
| Shareholder Yield | -1.25% |
| Earnings Yield | 0.41% |
| FCF Yield | -4.31% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |